相关实验视频
Updated: Jul 1, 2025

08:50
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
7.0K
用生物标志物优化治疗的成本效益,用于固体瘤免疫疗法:系统性审查
Sara Mucherino1, Valentina Lorenzoni2, Isotta Triulzi2
1CIRFF-Centre of Pharmacoeconomics and Drug Utilization Research, Department of Pharmacy, University of Naples Federico II, via D Montesano 49, 80131 Naples, Italy.
Cancers
|March 13, 2024
概括
预测性生物标志物测试,如对免疫检查点抑制剂 (ICI) 的PD-L1评估,在非小细胞肺癌中显示出成本效益. 然而,对于其他固体瘤来说,实现这一目标仍然是一个挑战.
科学领域:
- 卫生经济学 卫生经济学
- 在瘤学瘤学.
- 生物标志物研究 生物标志物研究
背景情况:
- 免疫检查点抑制剂 (ICI) 已经彻底改变了癌症治疗.
- 预测性生物标志物对于优化ICI治疗疗效至关重要.
- 需要健康经济评估来评估生物标志物测试的价值.
研究的目的:
- 对ICI治疗的实体瘤进行预测生物标志物测试的健康经济评估进行审查.
- 为了确定特定的生物标志物和瘤类型,测试具有成本效益.
- 评估ICI治疗中的预测生物标志物测试的整体成本效益格局.
主要方法:
- 在PubMed,EMBASE和Web of Science的系统文献搜索 (2010年6月 - 2022年2月).
- 选了730篇文章,其中包括58项相关研究在审查中.
- 专注于非小细胞肺癌 (NSCLC) 和其他固体瘤.
主要成果:
- 在35项NSCLC研究中,有21项研究表明,使用pembrolizumab对PD-L1评估具有成本效益.
- PD-L1测试在NSCLC,尿路细胞癌和细胞癌中具有成本效益.
- 没有任何经济评估达到膀,宫和三阴性乳腺癌的10万美元/QALY值.
结论:
- PD-L1表达测试是ICI治疗的成本有效策略,特别是在NSCLC.
- 对于某些固体瘤的预测生物标志物测试的成本效益仍然存在不确定性.
- 生物标志物测试显示了潜在的价值,特别是布罗利祖马布在NSCLC中,但对其他癌症仍然存在挑战.
相关概念视频
Tumor Immunotherapy
524
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
524
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

